blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2575762

EP2575762 - REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  22.04.2022
Database last updated on 11.05.2024
FormerThe patent has been granted
Status updated on  05.04.2022
Most recent event   Tooltip22.04.2022Revocation of patentpublished on 25.05.2022  [2022/21]
Applicant(s)For all designated states
Baxalta Incorporated
1200 Lakeside Drive
Bannockburn, IL 60015 / US
For all designated states
Baxalta GmbH
Thurgauerstrasse 130
8152 Glattpark (Opfikon) / CH
[2020/17]
Former [2017/47]For all designated states
Baxalta Incorporated
1200 Lakeside Drive
Bannockburn, IL 60015 / US
For all designated states
Baxalta GmbH
Zählerweg 4
6300 Zug / CH
Former [2016/43]For all designated states
Baxalta Incorporated
1200 Lakeside Drive
Bannockburn, IL 60015 / US
For all designated states
Baxalta GmbH
Thurgauerstrasse 130
8152 Glattpark, Opfikon / CH
Former [2013/15]For all designated states
Baxter International Inc
One Baxter Parkway
Deerfield, IL 60015 / US
For all designated states
Baxter Healthcare SA
Thurgauerstrasse 130
8152 Glattpark (Opfikon) / CH
Inventor(s)01 / TESCHNER, Wolfgang
Gestettengasse 19/14
A-1030 Vienna / AT
02 / SCHWARZ, Hans-Peter
Weimarer Strasse 76
A-1180 Vienna / AT
03 / MADLENER, Ruth
Grobe Pfarrgasse 6/9
A-1020 Vienna / AT
04 / SVATOS, Sonja
Kapellengasse 42
A-2413 Berg / AT
05 / PLJEVLJAKOVIC, Azra
Ottakringerstrasse 94/22
A-1170 Vienna / AT
06 / WEBER, Alfred
Skraupstrasse 24/42/8
A-1210 Vienna / AT
 [2013/15]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2013/15]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Application number, filing date11729200.326.05.2011
WO2011US38247
Priority number, dateUS2010078936527.05.2010         Original published format: US 789365
US2010084294423.07.2010         Original published format: US 842944
AU2010020212526.05.2010         Original published format: AU 2010202125
[2013/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011150284
Date:01.12.2011
Language:EN
[2011/48]
Type: A2 Application without search report 
No.:EP2575762
Date:10.04.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2011 takes the place of the publication of the European patent application.
[2013/15]
Type: B1 Patent specification 
No.:EP2575762
Date:09.07.2014
Language:EN
[2014/28]
Search report(s)International search report - published on:EP24.05.2012
ClassificationIPC:A61K38/17, C07K1/36, C07K16/06, A61K35/16, A61K9/08, C07K1/30, A61K47/18, A61K9/00
[2014/01]
CPC:
C07K1/36 (EP,AU,EA,US); A61K35/16 (EP,AU,US); A61K9/08 (EP,KR,US);
A61K39/395 (EA); A61K38/17 (KR); A61K38/1709 (EP,US);
A61K38/57 (AU); A61K39/39525 (US); A61K47/18 (KR);
A61K47/183 (EP,US); A61K9/00 (KR); A61K9/0019 (EP,US);
A61K9/0026 (EP); A61P13/12 (EP); A61P27/02 (EP);
A61P31/00 (EP); A61P37/00 (EP,EA); A61P37/02 (EP);
A61P37/04 (EP); A61P37/06 (EP); A61P7/00 (EP);
B01D15/12 (US); B01D15/362 (US); B01D15/363 (US);
B01D15/424 (US); B01J20/10 (EA); C07K1/30 (EP,US);
C07K16/00 (KR); C07K16/06 (EA); C07K16/065 (EP,US);
C07K1/14 (US); C07K1/18 (US); C07K1/34 (US) (-)
Former IPC [2013/15]A61K9/08, A61K47/18, A61K9/00, A61K38/17, C07K16/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ENTFERNUNG VON SERINPROTEASEN DURCH BEHANDLUNG MIT FEINTEILIGEM SILIZIUMDIOXID[2014/01]
English:REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE[2013/15]
French:ELIMINATION DE SERINE PROTEASES PAR TRAITEMENT AVEC DU DIOXYDE DE SILICIUM FINEMENT DIVISE[2014/03]
Former [2013/15]ENTFERNUNG VON SERINPROTEASEN MITTELS BEHANDLUNG VON FEINGETEILTEM SILICIUMDIOXID
Former [2013/15]ELIMINATION DE SERINE PROTEASES PAR TRAITEMENT AVEC DU DIOXYDE DE SILICIUM FINEMENT DIVISE
Entry into regional phase20.12.2012National basic fee paid 
20.12.2012Designation fee(s) paid 
20.12.2012Examination fee paid 
Examination procedure20.12.2012Examination requested  [2013/15]
02.08.2013Amendment by applicant (claims and/or description)
17.12.2013Communication of intention to grant the patent
28.04.2014Fee for grant paid
28.04.2014Fee for publishing/printing paid
28.04.2014Receipt of the translation of the claim(s)
Divisional application(s)EP14166189.2  / EP2796128
EP22164436.2
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.12.2013
Opposition(s)Opponent(s)01  31.03.2015  09.04.2015  ADMISSIBLE
Octapharma AG
Seidenstrasse 2
8853 Lachen / CH
Opponent's representative
Ullrich & Naumann PartG mbB, et al, et al
Schneidmühlstrasse 21
69115 Heidelberg / DE
 02  09.04.2015  13.04.2015  ADMISSIBLE
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Opponent's representative
Carpmaels & Ransford LLP, et al, et al
One Southampton Row
London WC1B 5HA / GB
 [2021/37]
Former [2016/10]
Opponent(s)01  31.03.2015  09.04.2015  ADMISSIBLE
Octapharma AG
Seidenstrasse 2
8853 Lachen / CH
Opponent's representative
Patent- und Rechtsanwälte Ullrich & Naumann, et al, et al
PartG mbB
Schneidmuehlstrasse 21
69115 Heidelberg / DE
 02  09.04.2015  13.04.2015  ADMISSIBLE
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Opponent's representative
Wise, Daniel Joseph, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
GB-London WC1B 5HA / GB
Former [2015/21]
Opponent(s)01  31.03.2015  09.04.2015  ADMISSIBLE
Octapharma AG
Seidenstrasse 2
8853 Lachen / CH
Opponent's representative
Von Kreisler Selting Werner - Partnerschaft von Patentanwälten und Rechtsanwälten mbB, et al, et al
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
 02  09.04.2015   
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Opponent's representative
Wise, Daniel Joseph, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
GB-London WC1B 5HA / GB
Former [2015/19]
Opponent(s)01  31.03.2015   
Octapharma AG
Seidenstrasse 2
8853 Lachen / CH
Opponent's representative
Von Kreisler Selting Werner - Partnerschaft von Patentanwälten und Rechtsanwälten mbB, et al, et al
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
15.05.2015Invitation to proprietor to file observations on the notice of opposition
25.11.2015Reply of patent proprietor to notice(s) of opposition
12.06.2018Date of oral proceedings
28.06.2018Despatch of a communication from the opposition division (Time limit: M02)
28.06.2018Despatch of minutes of oral proceedings
03.09.2018Reply to a communication from the opposition division
26.09.2018Despatch of a communication from the opposition division (Time limit: M02)
29.11.2018Reply to a communication from the opposition division
05.09.2019Date of oral proceedings
03.12.2019Despatch of interlocutory decision in opposition
03.12.2019Despatch of minutes of oral proceedings
04.04.2022Despatch of communication that the patent will be revoked
14.04.2022Legal effect of revocation of patent [2022/21]
Appeal following opposition12.02.2020Appeal received No.  T0319/20
30.04.2020Statement of grounds filed
22.03.2022Result of appeal procedure: revocation of the patent
04.04.2022Despatch of the decision of the Board of Appeal
12.02.2020Appeal received No.  T0319/20
17.04.2020Statement of grounds filed
22.03.2022Result of appeal procedure: revocation of the patent
04.04.2022Despatch of the decision of the Board of Appeal
03.02.2020Appeal received No.  T0319/20
09.04.2020Statement of grounds filed
22.03.2022Result of appeal procedure: revocation of the patent
04.04.2022Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
28.05.2013Renewal fee patent year 03
27.05.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.07.2014
CY09.07.2014
EE09.07.2014
MC09.07.2014
MK09.07.2014
MT09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
SM09.07.2014
IS09.11.2014
[2018/46]
Former [2018/31]CY09.07.2014
EE09.07.2014
MC09.07.2014
MK09.07.2014
MT09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
SM09.07.2014
IS09.11.2014
Former [2017/38]CY09.07.2014
EE09.07.2014
MC09.07.2014
MT09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
SM09.07.2014
IS09.11.2014
Former [2017/03]CY09.07.2014
EE09.07.2014
MC09.07.2014
MT09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
IS09.11.2014
Former [2016/06]CY09.07.2014
EE09.07.2014
MC09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
IS09.11.2014
Former [2015/50]CY09.07.2014
EE09.07.2014
RO09.07.2014
RS09.07.2014
SI09.07.2014
IS09.11.2014
Former [2015/23]CY09.07.2014
EE09.07.2014
RO09.07.2014
RS09.07.2014
IS09.11.2014
Former [2015/22]CY09.07.2014
RO09.07.2014
RS09.07.2014
IS09.11.2014
Former [2015/12]CY09.07.2014
RS09.07.2014
IS09.11.2014
Former [2015/11]CY09.07.2014
Cited inInternational search[X]WO2007085626  (OCTAPHARMA AG [CH], et al) [X] 1-115 * paragraph [0010] - paragraph [0032] * * claims 1-29 *;
 [A]US2009203580  (DINARELLO CHARLES A [US], et al) [A] 1-115* claims 1-28 *
by applicantSE348942
 US5122373
 US5177194
 EP0698615
 US5886154
 US6069236
 US6093324
 US6413245
 US6835379
 WO2005073252
 US6974792
 US7186410
 WO2007066017
 WO2008113589
 US2009148463
 US7553938
 US7807435
 WO2011011753
    - LIM ET AL., J INFECT DIS., (20030915), vol. 188, no. 6, pages 919 - 26
    - OPAL ET AL., CRIT CARE MED., (200702), vol. 35, no. 2, pages 387 - 92
    - JOURDAIN ET AL., AM J RESPIR CRIT CARE MED., (199712), vol. 156, no. 6, pages 1825 - 33
    - YANG ET AL., CRIT CARE MED., (200203), vol. 30, no. 3, pages 617 - 22
    - LIM ET AL., J INFECT DIS., (20030315), vol. 188, no. 6, pages 919 - 26
    - WU ET AL., CRIT CARE MED., (200408), vol. 32, no. 8, pages 1747 - 52
    - WOLBERG AS ET AL., "Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations", AM J HEMATOL, vol. 65, doi:doi:10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J, pages 30 - 34, XP055193310

DOI:   http://dx.doi.org/10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J
    - ALVING BM ET AL., "Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties", J LAB CLIN MED, (1980), vol. 96, pages 334 - 346, XP003035476
    - "Molecular Biology of Human Proteins", SCHULTZE H E, HEREMANS J F, Nature and Metabolism of Extracellular Proteins, ELSEVIER PUBLISHING COMPANY, (1966), vol. I, pages 236 - 317
    - RIPOCHE ET AL., BIOCHEM. J., (1988), vol. 249, pages 593 - 602
    - BARLOW ET AL., ADV EXP MED BIOL., (2008), vol. 632, pages 117 - 42
    - DE CORDOBA, DE JORGE, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (2008), vol. 151, pages 1 - 13
    - KARDYS ET AL., JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, (2006), vol. 47, pages 1568 - 1575
    - MOOIJAART ET AL., EXPERIMENTAL GERONTOLOGY, (2007), vol. 42, pages 1116 - 1122
    - NICAUD ET AL., JOURNAL OF MOLECULAR MEDICINE, (2007), vol. 85, pages 771 - 775
    - PAI ET AL., EUROPEAN HEART JOURNAL, (2007), vol. 28, pages 1297 - 1303
    - STARK ET AL., CLINICAL SCIENCE (LOND, (2007), vol. 113, pages 213 - 218
    - MENG ET AL., BMC MEDICAL GENETICS, (2007), vol. 8, page 62
    - PULIDO ET AL., MAYO CLINIC PROCEEDINGS, (2007), vol. 82, pages 301 - 307
    - TOPOL ET AL., HUMAN MOLECULAR GENETICS, (2006), vol. 15, no. 2, pages RL 17 - R123
    - HAMILTON ET AL., NEUROMOLECULAR MEDICINE, (2007), vol. 9, pages 331 - 334
    - ZETTERBERG ET AL., AMERICAN JOURNAL OF OPHTHALMOLOGY, (2007), vol. 143, pages 1059 - 1060
    - LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, (1992), vol. 1-3
    - J. AM. CHEM. SOC., (1946), vol. 68, no. 3, pages 459 - 475
    - J. AM. CHEM. SOC., (1950), vol. 72, pages 465 - 474
    - J. AM. CHEM. SOC., (1949), vol. 71, no. 2, pages 541 - 550
    - J. BIOL. CHEM., vol. 164, pages 109 - 118
    - MUNCH MED WOCHENSCHR, (1967), pages 1749 - 1752
    - VOX SANG, (2003), pages 193 - 201
    - BRAZ J MED BIOL RES, (2000), pages 37 - 30
    - VOX SANG, (2007), pages 42 - 55
    - HELV. CHIM. ACTA, vol. 37, pages 866 - 873
    - VOX SANG, (1962), vol. 7, pages 414 - 424
    - VOX SANG., (1962), vol. 7, pages 157 - 74
    - VOX SANG, (1967), vol. 13, pages 93 - 102
    - TESCHNER W ET AL., VOX SANG., (200701), vol. 92, no. 1, pages 42 - 55
    - NAGASAWA S, STROUD R M, MOL IMMUNOL, (1980), vol. 17, pages 1365 - 72
    - CROSSLEY L G, PORTER R R, BIOCHEM J, (1980), vol. 191, pages 173 - 82
    - RIPOCHE J, AL SALIHI A, ROUSSEAUX J, FONTAINE M, BIOCHEM J, (1984), vol. 221, pages 89 - 96
    - COHN ET AL., J. AM. CHEM. SOC., (1946), vol. 68, pages 459 - 75
    - ONCLEY ET AL., J. AM. CHEM. SOC., (1949), vol. 71, pages 541 - 50
    - BARUNDERN ET AL., VOX SANG, (1962), vol. 7, pages 157 - 74
    - KOBLET ET AL., VOX SANG, (1967), vol. 13, pages 93 - 102
    - DEUTSCH ET AL., J. BIOL. CHEM., vol. 164, pages 109 - 118
    - COHN ET AL., J. AM. CHEM. SOC., (1950), vol. 72, pages 465 - 474
    - COHN ET AL., Blood Cells and Plasma Proteins: Their State in Nature, ACADEMIC PRESS, (1953), pages 1 - 58
    - NITSCHMANN ET AL., HELV. CHIM. ACTA, vol. 37, pages 866 - 873
    - KISTLER, NITSCHMANN, VOX SANG., (1962), vol. 7, pages 414 - 424
    - BARUNDEM ET AL., VOX SANG., (1962), vol. 7, pages 157 - 74
    - KOBLET ET AL., VOX SANG., (1967), vol. 13, pages 93 - 102
    - HOROWITZ ET AL., BLOOD COAGUL FIBRINOLYSIS, (1994), no. 5, pages S21 - S28
    - KREIL ET AL., TRANSFUSION, (2003), pages 1023 - 1028
    - HAMAMOTO ET AL., VOX SANG, (1989), pages 230 - 236
    - YUASA ET AL., J GEN VIROL., (1991), pages 2021 - 2024
    - KEMPF ET AL., TRANSFUSION, (1991), pages 423 - 427
    - LOUIE ET AL., BIOLOGICALS, (1994), pages 13 - 19
    - PISZKIEWICZ ET AL., THROMB RES., (19870715), vol. 47, no. 2, pages 235 - 41
    - PISZKIEWICZ ET AL., CURR STUD HEMATOL BLOOD TRANSFUS, (1989), pages 44 - 54
    - EPSTEIN, FRICKE, ARCH PATHOL LAB MED., (199003), vol. 114, no. 3, pages 335 - 40
    - VOX SANG., (1962), vol. 7, pages 414 - 424
    - FELDMAN, WINKELMAN, Blood Separation and Plasma Fractionation, WILEY-LISS, INC., (1991), pages 341 - 383
    - BASIS ET AL., VOPR. MED. KHIM., (1987), vol. 33, no. 1, pages 54 - 59
    - YUASA ET AL., J GEN VIROL., (1991), vol. 72, pages 2021 - 2024
OppositionEP0893450
 WO2005082937
 US3998946
 US4136094
 US4216205
 US4228154
 US4272523
 US4296027
 US4318902
 US4439358
 US4503039
 US6093324
 WO2004060528
 WO2005073252
 WO2007085626
 US2009203580
 WO2010056909
 AU2010202125B
 AU2010224461
 WO2010138736
 WO2011011753
 US2011021432
 WO2011149472
 WO2012012773
    - "Diatomaceous earth", Wikipedia, (20180407), URL: https://en.wikipedia.org/wiki/Diatomaceous_earth, XP055482211
    - P. R. FOSTER, "Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopath y", Transfusion Medicine, (19990000), vol. 9, doi:10.1046/j.1365-3148.1999.009001003.x, pages 3 - 14, XP000904838

DOI:   http://dx.doi.org/10.1046/j.1365-3148.1999.009001003.x
    - CHARLES G. COCHRANE et al., "Molecular Assembly in the Contact Phase of the Hageman Factor System", The American Journal of Medicine, (19791001), vol. 67, no. 4, pages 657 - 664, XP026371377

DOI:   http://dx.doi.org/10.1016/0002-9343(79)90253-5
    - J. M. CURLING, Methods of Plasma Protein Fractionation, Academic Press, (19800000), pages 244 - 259
    - E. J. COHN et al., "A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids", Preparation and Properties of Serum and Plasma Proteins, (19460301), vol. 68, doi:10.1021/ja01207a034, pages 459 - 475, XP001148358

DOI:   http://dx.doi.org/10.1021/ja01207a034
    - SANDRA SCHIFFMAN et al., "Partial Purification and Characterization of Contact Activation Cofactor", The Journal of Clinical Investigation, (19751101), vol. 56, no. 5, pages 1082 - 1092, XP055741744

DOI:   http://dx.doi.org/10.1172/JCI108182
    - Anonymous, "Diatomaceous earth", Wikipedia, the free encyclopedia, (20200407), URL: https://en.wikipedia.org/w/index.php?title=Diatomaceous_earth&oldid=835317216, XP055482211
    - Octapharma USA, "FDA Approves U.S. Market Return for Octagam Following Octapharma's Implementation of Enhanced Safety Measures", PR Newswire - Press realease, (20111104), URL: https://www.prnewswire.com/news-releases/fda-approves-us-market-return-for-octagam-following-octapharmas-implementation-of-enhanced-safety-measures-133246738.html, XP055741797
    - anonymous, "WHO International Standard 2nd International Standard For Prekallikrein Activator", NIBSC code: 02/168 Instructions for use, (20080326), URL: https://www.nibsc.org/documents/ifu/02-168.pdf, XP055741806
    - SMITH et al., "How it all starts: Initiation of the clotting cascade", Crit Rev Biochem Mol Biol., (20150704), vol. 50, no. 4, pages 326 - 336, XP055741746

DOI:   http://dx.doi.org/10.3109/10409238.2015.1050550
    - WUILLEMIN et al., "Modulation of Contact System Proteases by Glycosaminoglycans", The Journal of Biological Chemistry, (19960501), vol. 271, no. 22, pages 12913 - 12918, XP055741748

DOI:   http://dx.doi.org/10.1074/jbc.271.22.12913
    - Anonymous, "BIOPHEN™ CS-21(66) Activated Protein C Chromogenic substrate", HYPHEN BioMed - Product Sheet, (20140607), pages 1 - 2, URL: https://www.hyphen-biomed.com, XP055741793
    - ONCLEY J. L. et al., "The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and beta1-Lipoprotein into Subfractions of Human Plasma", J. Am. Chem. Soc., (19490200), vol. 71, no. 2, pages 541 - 550, XP055741755
    - "Factor I to Furin", Haeberli, Human Protein Data, WILEY-VCH, (19980000), XP055741791

DOI:   http://dx.doi.org/10.1002/9783527619764.ch6
    - EMSLEY et al., "Structure and function of factor XI", Blood, (20100401), vol. 115, no. 13, doi:10.1182/blood-2009-09-199182, pages 2569 - 2577, XP055121321

DOI:   http://dx.doi.org/10.1182/blood-2009-09-199182
    - SEKIYA et al., "Regulation of the Tertiary Structure and Function of Coagulation Factor IX by Magnesium(II) lons", The Journal of Biological Chemistry, (19950000), vol. 270, no. 24, doi:10.1074/jbc.270.24.14325, pages 14325 - 14331, XP002125729

DOI:   http://dx.doi.org/10.1074/jbc.270.24.14325
    - WOLBERG AS et al., "Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations", Am J Hematol, (20000000), vol. 65, pages 30 - 34, XP009191076
    - Anonymous, "GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%", Baxter, (20050400), pages 1 - 4, URL: https://www.baxter.com.pr/downloads/healthcare_professionals/products/GGLIQ_PI.pdf, XP002542175
    - Anonymous, "Highlights of Prescribing Information for Gammagard Liquid 10%", FDA, (20120600), pages 1 - 43, URL: https://www.fda.gov/media/70812/download, XP055741758
    - HIRSCH F. et al., "The Electrical Conductivity of Blood", Blood, (19500000), vol. 5, no. 11, pages 1017 - 1035, XP055652336
    - Anonymous, "Low Frequency (Conductivity)", IT'IS Foundation - Tissue Properties, (20190503), URL: https://itis.swiss/virtual-population/tissue-properties/database/low-frequency-conductivity, XP055741764
    - Anonymous, "acid-base homeostasis", Wikipedia, the free encyclopedia, (20200909), pages 1 - 6, URL: https://en.wikipedia.org/wiki/Acid%E2%80%93base_homeostasis, XP055741772
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.